Ticker LaunchUplisting · ZIVO
Zivo Bioscience, Inc.
Formerly HEALTH ENHANCEMENT PRODUCTS INC; WESTERN GLORY HOLE INC
Zivo Bioscience, Inc. (ZIVO), already reporting to the SEC, moved up to Nasdaq Capital Market on Jun 1, 2021 with an offering at $0.01 per share raising $13.8M. Maxim Group was lead-left underwriter, joined by Joseph Gunnar. Honigman advised the company and Gracin & Marlow advised the underwriters.
Zivo Bioscience, Inc. is a research and development company in biotech and agtech with a portfolio of proprietary algal and bacterial strains and bioactive compounds. It targets human and animal health uses such as poultry coccidiosis and cholesterol, and its algal biomass is produced in Arizona, India and Peru.
- Status
- Uplisting
- Ticker
- ZIVO
- Exchange
- Nasdaq Capital Market
- Listed
- Jun 1, 2021
- Price
- $0.01
- Raised
- $13.8M
- First filed
- Dec 9, 2020
- Underwriters
- Maxim Group and Joseph Gunnar
- Company counsel
- Honigman
- Underwriters' counsel
- Gracin & Marlow
- Sector
- Biotech & pharma
- Country / state
- MI
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Dec 9, 2020
- Latest amendment May 26, 2021
- Final prospectus (424B4) Jun 1, 2021
- All filings on EDGAR CIK 1101026
Other Biotech & pharma uplistings in 2021
- Evotec SEEVO · Nov 5, 2021 · $435M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- Protagenic Therapeutics, Inc.\newPTIX · Apr 28, 2021 · $13.2M
- GT Biopharma, Inc.GTBP · Feb 12, 2021 · $23.6M
- Lexaria Bioscience Corp.LEXX · Jan 14, 2021 · $9.6M
- Zevra Therapeutics, Inc.KMPH · Jan 11, 2021